Australia’s regulatory environment for implantable medical devices is changing rapidly. As both a sponsor and manufacturer, I’ve seen first-hand how increased scrutiny and a shift toward real-world evidence is reshaping our sector. These changes are more than just procedural; they are a necessary evolution to support patient safety, clinical confidence and long-term innovation.

As sponsors, we are now expected to think well beyond the pre-market phase. Regulatory responsibility does not end with product approval. In many ways, that is where it begins.

Understanding the Full Lifecycle

It is critical to understand the entire lifecycle of a medical device, from intellectual property and pre-market clinical data to the nuances of post-market surveillance. One of the first considerations is patent protection. While not always front of mind, patents can provide 20 years of exclusive commercial rights and help protect innovation globally.

When preparing a submission to the Therapeutic Goods Administration (TGA), having robust clinical data is essential. While double-blinded placebo trials remain the gold standard, they are often not feasible for implantable devices. Instead, comparative studies against the current gold standard are acceptable, and they are now expected to extend to at least two years.

Knowing your device’s classification is equally important. For example, Class I devices often bypass in-depth review unless sterility or measurement functions are involved. But Class III devices, where I have the most experience, undergo far more rigorous evaluation including audits and conformity assessments.

Leveraging International Approvals

There is encouraging momentum in regulatory harmonisation. The TGA increasingly accepts data from comparable approvals such as the US FDA’s 510(k) or PMA pathways. This can streamline local approval, but it is important to remember that global data must still be supplemented with strong clinical evidence relevant to the Australian market.

This flexibility can be especially valuable when sponsors are using data from similar devices already in market. However, alignment with Australian regulatory expectations must always be a priority.

Learning From Recent Cases

Recent cases serve as stark reminders of what is at stake. The $22 million penalty issued to Medtronic by the Federal Court for the unlawful supply of a bone graft product without its paired cage shows how critical it is to understand the approved indications and ARTG listings. Even when a product is listed, separating it from its approved use can create serious compliance risks.

Another pivotal example involves spinal cord stimulators. After years on the ARTG and thousands of implantations, a combination of adverse event reports and media attention triggered an industry-wide review. This led to post-market conditions being placed on 70 devices, while 12 were removed from the register. It was a clear message from the TGA that approval is not permanent and that evidence must be maintained.

The Growing Role of Registries

Real-world data has become central to this shift. National device registries, such as the orthopaedic registry which tracks over 1.5 million joint replacements, are proving invaluable. They support early signal detection, improve post-market surveillance and provide insights into long-term device performance.

For sponsors and manufacturers, registries offer a structured way to demonstrate the ongoing safety and effectiveness of our devices. But challenges remain. Participation needs to be consistent and ideally mandatory. We also need to agree on what data should be collected, whether clinical events like revisions or broader outcomes like quality of life.

Where We’re Headed

Globally, we are seeing the same trend. There are stronger post-market requirements, greater reliance on real-world data, and increasing alignment across regulatory jurisdictions. This is a positive development for patients and for the credibility of our sector.

For sponsors and manufacturers, it is time to shift from compliance to commitment. Commitment to building evidence, monitoring outcomes and putting patients at the centre of every device we bring to market.

This new chapter is challenging. It is also an opportunity to demonstrate that the medical device sector in Australia is not just compliant, but world leading.